Amgen, Akcea Therapeutics and The Lipoprotein(a) Foundation give support for forthcoming Lipoprotein Exhibit at the Museum. Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. Akcea Therapeutics is a development and commercialization company focused on helping patients living with serious and rare diseases. Both Amgen and Akcea currently have Lipoprotein(a) lowering drugs in development. The Lipoprotein(a) Foundation‘s goal is to save lives by increasing awareness, advocating for routine testing, and a specific treatment for patients with risk related to elevated Lipoprotein(a) concentration.
The forthcoming Lipoprotein Exhibit will educate visitors on the various lipids and lipoproteins in the body and how they affect an individual’s cardiovascular health. The exhibit will highlight the work and discoveries made by the late Dr. Angelo Scanu, which advanced our understanding of the Lipoprotein(a) particle.
The exhibit opens to the public on November 11, 2018.